A Study of YM155 Plus Rituximab in Subjects With Non-Hodgkin's Lymphoma Who Have Received Prior Treatment
Status:
Completed
Trial end date:
2015-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate response rate, survival, safety and tolerability of
YM155 given in combination with rituximab in subjects with Non-Hodgkin's Lymphoma.